Tonsils - large
Also known as: Macro, Large
Methodology & AI Transparency ⓘ
Tonsils - large Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Tonsils - large (also termed Macro or Large) (J35.1; Ear, Nose, Throat & Oral Health) utilize hearing protection/amplification [Tonsils - large J35.1] and objective Pure-Tone Audiometry & in Tonsils - large (J35.1: Tympanometry) targets (Thresholds <= 20 dB HL; normal middle-ear pressure (J35.1)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Synonyms for Tonsils - large (J35.1): Macro, Large (ENT & Hearing).
- 3 Typical cash cost range: Differential triage of Tonsils - large (J35.1) utilizes hearing protection/amplification [Tonsils - large J35.1].
- 4 Top reported side effects / signs: Key ENT & Hearing biomarkers for Tonsils - large (J35.1): Pure-Tone Audiometry & in Tonsils - large (J35.1: Tympanometry) & Periodontal Pocket Depth in Tonsils - large (J35.1: & Bleeding Index) (Probing <= 3 mm without bleeding (J35.1)).
Ask our AI Specialists anything about Tonsils - large
What Is Tonsils - large?
Physicians managing Tonsils - large (also termed Macro or Large) (J35.1; Ear, Nose, Throat & Oral Health) utilize hearing protection/amplification [Tonsils - large J35.1] and objective Pure-Tone Audiometry & in Tonsils - large (J35.1: Tympanometry) targets (Thresholds <= 20 dB HL; normal middle-ear pressure (J35.1)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Tonsils - large (J35.1) alters ent & hearing homeostasis through Eustachian tube dysfunction [Tonsils - large J35.1]; clinical remission targets Periodontal Pocket Depth in Tonsils - large (J35.1: & Bleeding Index) within Probing <= 3 mm without bleeding (J35.1).
Common Symptoms & Clinical Signs
- • Presentation of Tonsils - large (J35.1): muffled hearing, ear in Tonsils - large (J35.1: fullness, popping pressure,)
- • Secondary Tonsils - large clinical sign: acute earache, sore in Tonsils - large (J35.1: throat with painful)
- • Symptom flares in Tonsils - large correlating with Pure-Tone Audiometry & in Tonsils - large (J35.1: Tympanometry) deviation outside Thresholds <= 20 dB HL; normal middle-ear pressure (J35.1)
- • Functional ent & hearing impact requiring hearing protection/amplification [Tonsils - large J35.1] evaluation (J35.1)
Tonsils - large Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J35.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Ear, Nose, Throat & Oral Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Pure-Tone Audiometry & in Tonsils - large (J35.1: Tympanometry) | Thresholds <= 20 dB HL; normal middle-ear pressure (J35.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Periodontal Pocket Depth in Tonsils - large (J35.1: & Bleeding Index) | Probing <= 3 mm without bleeding (J35.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Tonsils - large
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Small and Large Intestine Sarcode (Colon (Suis), Intestine (Suis)) Small and Large Intestine Sarcode • RxCUI RXN-B830270065 | Over-the-Counter Clinical Monograph | 81% | $1.5000 | $ 116.50 /mo |
| Sodium Phosphates Sodium Phosphates Generic • RxCUI 1872384 | FDA Prescription Therapeutic Agent | 89% | $2.2300 | $ 98.82 /mo |
| Sodium Acetate Sodium Acetate Generic • RxCUI 1859490 | Osmotic Laxative | 81% | $1.5600 | $ 71.68 /mo |
| Potassium Acetate Potassium Acetate Generic • RxCUI 1871155 | Osmotic Laxative | 87% | $0.4600 | $ 27.13 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tonsils - large)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Sustained real-world benefits and safety of guselkumab in patients with The majority of treatment-emergent side effects (TEAE) were mild to moderate (~88%) with low incidence of serious TEAE (7.6%). The Journal of dermatology • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34453358 ↗ |
| New Insights on Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in: What a 203-Participant Study Found A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-05-18 • Phase III Randomized Trial | N = 203 | 88/100 | PMID 33462580 ↗ |
| New Insights on Twenty-year survival of advanced gastrointestinal stromal tumours treated with: What a 434-Participant Study Found This long-term follow-up of the BFR14 trial shows long-term efficacy of imatinib in patients with advanced GIST. Annals of oncology : official journal of the European Society for Medical Oncology • 2025-09-15 • Phase III Randomized Trial | N = 434 | 87/100 | PMID 40447230 ↗ |
| Can This Approach Help? Inside the Latest Research on Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment Pretreatment transcriptome predicts first-year growth response in somapacitan-treated children with GHD. The Journal of clinical endocrinology and metabolism • 2024-04-19 • Phase III Randomized Trial | N = 76 | 82/100 | PMID 38066644 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of telmisartan on the nuclear factor of activated T lymphocytes Blood-pressure-lowering function and inhibitory effects of telmisartan on the T lymphocyte NFAT signalling pathway are unlikely to affect the normal immune function of hypertensive patients. Journal of the renin-angiotensin-aldosterone system : JRAAS • 2016-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 27317303 ↗ |
Tonsils - large Patient Community & “People Like Me” Threads
Filter Tonsils - large community threads and patient logs by age, biological sex, dosage, and treatment duration.